Oil-controlling and bacteriostatic self-assembled supramolecular composition, preparation method, application and preparation thereof

Abstract

This invention discloses an oil-controlling and antibacterial self-assembled supramolecular composition, its preparation method, application, and formulation, relating to the field of skin care product technology. It includes a supramolecular self-assembled polymer host, surfactant, polyol, pH adjuster, and water. The raw materials of the supramolecular self-assembled polymer host include a main component, compound components, and active synergistic components. The main component uses macromolecular structural units such as glycyrrhizic acid and baicalin to dominate the self-assembly into a cyclodextrin-like inclusion framework. Compound components such as Magnolia officinalis bark extract, physalisol, and Glycyrrhiza uralensis extract serve as key guest / co-assembly units, embedding and stabilizing the framework through supramolecular self-assembly effects to form a cyclodextrin-like inclusion structure. The active synergistic components, through supramolecular self-assembly effects, are distributed at the interface of the cyclodextrin-like inclusion structure and amplify biological effects. The resulting self-assembled supramolecular composition possesses multiple biological functions, including oil control, antibacterial, anti-inflammatory, and skin repair.

Description

Technical Field

[0001] This invention relates to the field of skin care product technology, and more specifically, to an oil-controlling and antibacterial self-assembled supramolecular composition, its preparation method, application, and formulation. Background Technology

[0002] With the fast pace of life and increased stress, skin problems are on the rise. Oily, acne-prone skin is a common issue, characterized by excessive oil production (seborrhea), enlarged pores, sensitivity, and breakouts. Traditional acne treatments primarily utilize chemical antibacterial agents, retinoic acid, and antibiotics. However, these products often suffer from high levels of irritation, dependency, and potential side effects.

[0003] Plant extracts contain a variety of natural active ingredients with diverse structures and broad targets (such as flavonoids, phenolic acids, terpenes and chalcones), and have long been used as one of the raw materials for solving skin problems. However, plant extracts generally have problems such as poor water solubility, low photothermal stability, insufficient transdermal absorption, poor compatibility between components and easy oxidation and degradation, which makes it difficult to make reasonable use of their excellent biological activities.

[0004] In recent years, supramolecular self-assembly technology has emerged as an advanced technique that enables molecular units to spontaneously form ordered and stable aggregates based on non-covalent interactions. Its driving forces primarily include hydrogen bonds, van der Waals forces, hydrophobic interactions, electrostatic interactions, π-π stacking interactions, and host-guest recognition. Unlike traditional covalent chemistry, supramolecular self-assembly is characterized by dynamic reversibility, tunable structure, and strong environmental responsiveness, enabling the construction of ordered assemblies at the molecular level, such as vesicles, gels, nanofibers, helical structures, and host-guest inclusion complexes. Through synergistic recognition and directional arrangement between molecules, this technology can achieve the solubilization, stabilization, sustained release, and targeted delivery of active synergistic ingredients, showing broad application prospects in pharmaceutical formulations, functional materials, cosmetics, and separation science. The application of supramolecular self-assembly technology provides new insights for the development of acne treatment products. By modifying and compounding multiple active synergistic ingredients, both efficacy and irritation can be improved. However, due to their reliance on weak interactions to maintain their structure, supramolecular self-assembly systems generally suffer from high environmental sensitivity, poor stability, susceptibility to interference from formulation components, and a tendency to disassemble, precipitate, crystallize, or separate during storage or processing. These issues, to some extent, limit their industrial application and promotion. Therefore, there is still an urgent need for cosmetic products with good stability, high safety, and effective oil control and antibacterial properties.

[0005] In view of this, the present invention is proposed. Summary of the Invention

[0006] The purpose of this invention is to provide an oil-controlling and antibacterial self-assembled supramolecular composition, its preparation method, application, and formulation.

[0007] This invention is implemented as follows: In a first aspect, the present invention provides a self-assembled supramolecular composition comprising, by weight: 7.5 to 13 parts by weight of a supramolecular self-assembled polymeric host, 6 to 9 parts by weight of a surfactant, 35 to 42 parts by weight of a polyol, 1 to 2 parts by weight of a pH adjuster, and 34 to 50.5 parts by weight of water.

[0008] The raw materials of the supramolecular self-assembly polymer host include the main components, compound components and active synergistic components in a mass ratio of (1~5):(2~3):(4.5~5).

[0009] The main components include at least one of glycyrrhizic acid and baicalin.

[0010] The compound ingredients include at least one of the following: Magnolia officinalis bark extract, cypressin, and Glycyrrhiza uralensis extract.

[0011] The active synergistic ingredients include at least one of the following: white willow bark extract and succinic acid.

[0012] In a second aspect, the present invention provides a method for preparing a self-assembled supramolecular composition according to any of the foregoing embodiments, comprising: mixing a main component, a compound component and a polyol uniformly to obtain a first solution; adding a surfactant to the first solution and mixing uniformly to obtain a second solution; adding a pH adjuster to the second solution to obtain a third solution; and adding an active synergist to the third solution and mixing uniformly to obtain a self-assembled supramolecular composition.

[0013] Thirdly, the present invention provides a formulation comprising a self-assembled supramolecular composition of any of the foregoing embodiments or a self-assembled supramolecular composition prepared by the preparation method of the foregoing embodiments.

[0014] Fourthly, the present invention provides the use of a self-assembled supramolecular composition of any of the foregoing embodiments or a self-assembled supramolecular composition prepared by the preparation method of the foregoing embodiments in the preparation of an agent for at least one of oil control, antibacterial, prevention and / or improvement of acne vulgaris, skin repair, skin anti-inflammation and skin anti-oxidation.

[0015] The present invention has the following beneficial effects: This invention provides an oil-controlling and antibacterial self-assembled supramolecular composition, its preparation method, application, and formulation. The main components are macromolecular structural units such as glycyrrhizic acid and baicalin, which dominate the self-assembly into a cyclodextrin-like inclusion backbone. Compound components such as Magnolia officinalis bark extract, physalisol, and Glycyrrhiza uralensis extract serve as key guest / co-assembly units, embedding and stabilizing the backbone through supramolecular self-assembly effects to form a cyclodextrin-like inclusion structure. The active synergistic components are distributed at the interface of the cyclodextrin-like inclusion structure through supramolecular self-assembly effects and amplify biological effects, achieving the synergistic and sustained presentation of multiple biological effects such as oil control, antibacterial, anti-inflammatory, and skin repair of the self-assembled supramolecular composition. Attached Figure Description

[0016] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation on the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.

[0017] Figure 1 The particle size and light intensity distribution of the self-assembled supramolecular composition provided in Example 1 of this invention; Figure 2 The particle size and light intensity distribution of the composition provided in Comparative Example 1 of this invention; Figure 3 This is a particle size and light intensity distribution diagram of the composition provided in Comparative Example 12 of the present invention. Detailed Implementation

[0018] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.

[0019] In a first aspect, the present invention provides a self-assembled supramolecular composition comprising, by weight: 7.5 to 13 parts by weight of a supramolecular self-assembled polymeric host, 6 to 9 parts by weight of a surfactant, 35 to 42 parts by weight of a polyol, 1 to 2 parts by weight of a pH adjuster, and 34 to 50.5 parts by weight of water.

[0020] The raw materials of the supramolecular self-assembly polymer host include the main components, compound components and active synergistic components in a mass ratio of (1~5):(2~3):(4.5~5).

[0021] The main components include at least one of glycyrrhizic acid and baicalin.

[0022] The compound ingredients include at least one of the following: Magnolia officinalis bark extract, cypressin, and Glycyrrhiza uralensis extract.

[0023] The active synergistic ingredients include at least one of the following: white willow bark extract and succinic acid.

[0024] By selecting the raw materials of the main component, compound component, and active synergist provided by this invention, the hydrogen bonds, π-π stacking, and hydrophobic interactions formed between the main component (glycyrrhizic acid and / or baicalin) and the compound component (Magnolia officinalis bark extract, cypressin, and / or Glycyrrhiza uralensis extract) synergize with the amphiphilic structural characteristics of the active synergist (Salix psammophila bark extract and / or succinic acid), spontaneously forming thermodynamically stable and dynamically reversible nanoscale ordered aggregates in the microenvironment constructed by polyols and surfactants, resulting in a supramolecular self-assembly effect. This not only enhances the aqueous dispersibility and chemical stability of each functional component and effectively inhibits the degradation and precipitation of active components in various plant extracts such as Magnolia officinalis bark extract, but also responds to pH and lipid environment changes on the skin surface or in the stratum corneum microenvironment, achieving targeted enrichment and controllable release of the active synergist. Thus, while maintaining the physical uniformity and long-term storage stability of the system, it ensures the synergistic and continuous presentation of multiple biological effects such as oil control, antibacterial, anti-inflammatory, and skin repair.

[0025] In an optional embodiment, the Magnolia officinalis bark extract includes total magnolia officinalis phenols, and the content of total magnolia officinalis phenols in the Magnolia officinalis bark extract is ≥98.0 wt%; for example, the content of total magnolia officinalis phenols in the Magnolia officinalis bark extract is 98.0 wt%, 98.5 wt%, 99.0 wt%, 99.07 wt%, 99.1 wt%, 99.5 wt%, 99.9 wt%, 100.0 wt%, or any value within the range of any two of these values.

[0026] Preferably, the total phenols in magnolol include at least one of magnolol and honokiol.

[0027] Magnolia officinalis bark extract is derived from Magnolia officinalis, a plant belonging to the Magnoliaceae family. Magnolia officinalisMagnolia officinalis bark extract is a natural active ingredient obtained through low-temperature extraction of the dried root bark of Rehd., with magnolol and honokiol as its core active substances. In the cosmetics and skincare fields, magnolia officinalis bark extract possesses multiple benefits, including broad-spectrum antibacterial, potent anti-inflammatory, antioxidant, soothing and repairing, and skin barrier strengthening effects. It can significantly inhibit the proliferation of harmful microorganisms such as Propionibacterium acnes and Staphylococcus aureus, reduce the release of inflammatory factors (such as TNF-α and IL-6), and quickly soothe skin redness, stinging, and sensitivity. Simultaneously, it effectively scavenge free radicals, inhibit oxidative stress and matrix metalloproteinase activity, delaying photoaging and the formation of fine lines. It can also help strengthen the stratum corneum barrier, improve skin's water retention capacity, and alleviate dryness and roughness. It is commonly used in anti-acne, soothing and repairing, anti-aging, and sensitive skin care products. However, magnolol and honokiol are sensitive to light and temperature, requiring low-temperature, light-protected storage, which limits its application in the field of skin repair.

[0028] Preferably, cypressin (CAS: 499-44-5) is derived from Taiwan cypress (scientific name: Chamaecyparis obtusa (Sieb. et Zucc.) Endl. var. formosana Monoterpenoid compounds, such as cypress (Hayata) Rehd. and cypress arborvitae, are lipid-soluble and highly active ingredients, exhibiting poor dispersion stability in aqueous systems. Meanwhile, cypressin is renowned in skincare and personal care for its potent broad-spectrum antibacterial, anti-inflammatory, oil-controlling, hair loss-preventing, dandruff-reducing, and anti-itch properties: it has strong inhibitory effects on fungi (such as Malassezia and Candida albicans) and bacteria, and can replace traditional anti-dandruff agents in oil-controlling, dandruff-reducing, anti-acne, and antiseptic systems; it can effectively inhibit 5α-reductase activity, reduce dihydrotestosterone production, thereby regulating sebum secretion, improving scalp oiliness and hair follicle damage, and assisting in preventing hair loss and promoting hair growth; it can also downregulate pro-inflammatory mediators, soothe inflammation and redness, and has good skin permeability and is gentle and low-irritant.

[0029] Preferably, the extract of Glycyrrhiza inflata contains glycyrrhiza chalcone A; the content of glycyrrhiza chalcone A in the extract of Glycyrrhiza inflata is 21.0 wt% to 22.0 wt%; for example, the content of glycyrrhiza chalcone A in the extract of Glycyrrhiza inflata is 21.0 wt%, 21.2 wt%, 21.5 wt%, 21.7 wt%, 22.0 wt% or any value within the range of any two of these values.

[0030] In this invention, the extract of *Glycyrrhiza inflata* is derived from the legume *Glycyrrhiza inflata* (Glycyrrhiza inflata). Glycyrrhiza inflataThe root and rhizome of *B.* are refined and extracted, with glycyrrhizin A as the signature active ingredient, and rich in glycyrrhizic acid, glycyrrhetinic acid, glycyrrhizin flavonoids, and other effective components. Its skincare value focuses on highly effective anti-inflammatory and soothing, whitening and spot-fading, antioxidant, barrier repair, and skin brightening: it can significantly inhibit the NF-κB pathway and the release of inflammatory factors, quickly relieving skin erythema, stinging, and sensitivity stress, with outstanding repair effects on sensitive skin and post-cosmetic procedures; it blocks melanin synthesis by powerfully inhibiting tyrosinase activity, while accelerating pigment metabolism and improving dullness and pigmentation; the polysaccharide and flavonoid components can scavenge free radicals, protect collagen and elastin fibers, and improve skin hydration and barrier integrity. It is commonly used in whitening, anti-allergy, repairing, and anti-aging formulas, and is a classic anti-inflammatory and brightening ingredient in high-end skincare products.

[0031] Preferably, the white willow bark extract includes salicin, and the content of salicin in the white willow bark extract is ≥98wt%; for example, the content of salicin in the white willow bark extract is 98wt%, 98.15wt%, 98.2wt%, 98.5wt%, 99wt%, 99.5wt%, 99.9wt%, 100wt%, or any value within the range of any two of these values.

[0032] In this invention, the white willow bark extract is derived from the white willow (Salix psammophila), a plant of the Salicaceae family. Salix alba The dried bark of *L.* contains salicin (a natural precursor to salicylic acid), which is slowly converted into salicylic acid within the skin. Its core benefits include gentle exfoliation, unclogging pores, oil control and acne treatment, and anti-inflammatory and soothing effects: it gently exfoliates dead skin cells, dissolves keratin plugs, improves blackheads and enlarged pores, and is significantly less irritating than synthetic salicylic acid; it also possesses antibacterial and anti-inflammatory activities, inhibiting acne-related bacteria and reducing redness and swelling after acne; simultaneously, it regulates sebum secretion and maintains water-oil balance, leaving skin smooth and refreshed. Suitable for cleansers, toners, serums, acne treatments, and oil-control products, especially suitable for sensitive acne-prone skin and those who use mild acid-based products.

[0033] In this invention, succinic acid (CAS No.: 110-15-6) is a naturally occurring dibasic organic acid found in the metabolism of plants, animals, and the human body. It is a small-molecule amphiphilic component with good water solubility and is gentle and low-irritant. In the skincare field, it exhibits advantages such as oil control and acne clearing, anti-inflammatory repair, gentle skin resurfacing, and brightening and evening skin tone. It can inhibit Propionibacterium acnes, regulate sebaceous gland lipid synthesis, and reduce pore blockage and blackhead formation; by inhibiting the release of inflammatory factors and stabilizing the HIF-1α pathway, it quickly soothes acne redness and sensitivity; it promotes natural keratin metabolism through enzymatic regulation, while simultaneously strengthening the skin's water retention capacity, shrinking pores, and fading acne scars and dullness.

[0034] In this invention, on the one hand, the main component (at least one of glycyrrhizic acid and baicalin) and the compound component (at least one of Magnolia officinalis bark extract, cypressin, and Glycyrrhiza uralensis extract) can serve as structural units for supramolecular self-assembly compounding. Together with at least one active synergist from Salix babylonica bark extract and succinic acid, they can improve the compatibility of each component, avoid appearance problems such as layering, turbidity, precipitation, discoloration, and crystallization in the resulting supramolecular composition, and synergistically improve the content stability of each component (main component, guest component, and active synergist) in the resulting supramolecular composition. On the other hand, the main component and compound component used in this invention can also serve as active ingredients, forming a synergistic system with multiple targets, mechanisms, pathways, and effects (oil control, antibacterial, acne removal, skin repair, anti-inflammatory, and antioxidant effects) together with the active synergist, which can effectively solve the problems of lipid production and skin pigmentation.

[0035] In an optional embodiment, the surfactant includes at least one of oleyl alcohol polyether-20, lecithin, sophorolipid, and PPG-13-decyltetradecyl alcohol polyether-24.

[0036] Preferably, in order to specifically improve the structural stability of the supramolecular self-assembled polymeric host provided by the present invention, the surfactant includes: lecithin and at least one selected from oleyl alcohol polyether-20, sophorolipid, and PPG-13-decyltetradecyl alcohol polyether-24.

[0037] In some embodiments, the surfactant comprises lecithin and oleyl alcohol polyether-20 in a mass ratio of 1:4 to 6. In some embodiments, the surfactant comprises lecithin, sophorolipid, and PPG-13-decyltetradecyl alcohol polyether-24 in a mass ratio of 1:1.5 to 2.5:4.5 to 5.5.

[0038] In optional embodiments, the polyol includes at least one selected from dipropylene glycol, ethoxydiethylene glycol, and glycerol. Preferably, the polyol includes at least two selected from dipropylene glycol, ethoxydiethylene glycol, and glycerol. More preferably, the polyol includes dipropylene glycol and at least one selected from ethoxydiethylene glycol and glycerol.

[0039] In an optional embodiment, the pH adjuster includes at least one of L-arginine and sodium hydroxide.

[0040] In some embodiments, the weight parts of the main component can be 1 part by weight, 1.5 parts by weight, 2 parts by weight, 2.5 parts by weight, 3 parts by weight, 3.5 parts by weight, 4 parts by weight, 4.5 parts by weight, 5 parts by weight, or any value within any two of these values; the weight parts of the compound component can be 2 parts by weight, 2.1 parts by weight, 2.5 parts by weight, 3 parts by weight, or any value within any two of these values; the weight parts of the active synergist can be 4.5 parts by weight, 5 parts by weight, or any value within any two of these values; the weight parts of the surfactant can be 6 parts by weight, 6.5 parts by weight, 7 parts by weight, 7.5 parts by weight, 8 parts by weight, 8.5 parts by weight, 9 parts by weight, or any value within any two of these values; the weight parts of the polyol can be 35 parts by weight, 36 parts by weight, 37 parts by weight, 38 parts by weight, 39 parts by weight, 40 parts by weight, 41 parts by weight, 42 parts by weight, or any value within any two of these values. The pH adjuster can be 1 part by weight, 2 parts by weight, or any value within any two of these values; the water can be 34 parts by weight, 35 parts by weight, 35.5 parts by weight, 35.9 parts by weight, 40 parts by weight, 41 parts by weight, 42 parts by weight, 43 parts by weight, 44 parts by weight, 45 parts by weight, 46 parts by weight, 47 parts by weight, 48 parts by weight, 49 parts by weight, 50 parts by weight, 50.5 parts by weight, or any value within any two of these values.

[0041] Secondly, the present invention provides a method for preparing a self-assembled supramolecular composition according to any of the foregoing embodiments, comprising: mixing a main component, a compound component, and a polyol uniformly to obtain a first solution; adding a surfactant to the first solution and mixing uniformly to obtain a second solution; adding a pH adjuster to the second solution to obtain a third solution; and adding an active synergist to the third solution and mixing uniformly to obtain a self-assembled supramolecular composition. The present invention achieves controllable construction and functional integration of supramolecular structures through a strictly defined stepwise addition sequence.

[0042] In an optional embodiment, the method for preparing the self-assembled supramolecular composition provided by the present invention includes the following steps: S01. Mix the main component, compound component and polyol evenly to obtain the first solution.

[0043] In an optional embodiment, the mixing process to obtain the first solution is carried out by heating, with the heating temperature being 45°C to 65°C; for example, the heating temperature can be 45°C, 50°C, 55°C, 60°C, 65°C or any value within the range of any two of these values.

[0044] The main component and the compound components are dispersed together in a polyol and moderately heated to promote spontaneous assembly of the two through non-covalent forces such as hydrogen bonding, π-π stacking and hydrophobic interactions, forming an endogenous cavity structure with cyclodextrin-like characteristics. This structure can simulate the amphiphilic configuration of its hydrophobic inner cavity / hydrophilic outer surface without the need for exogenous cyclodextrin, thereby effectively encapsulating and stabilizing easily degradable hydrophobic active components such as magnolol, honokiol, physalisol and glycyrrhizin A, significantly improving the aqueous solubility, photostability and thermal stability of the active substances in the compound components.

[0045] S02. Add surfactant to the first solution and mix well to obtain the second solution.

[0046] Before the nascent self-assembled particles in step S01 aggregate or dissociate, a specific type and ratio of surfactant is immediately introduced to selectively anchor them at the interface of the self-assembled aggregates, forming a dynamic protective interfacial film. This inhibits irreversible aggregation driven by van der Waals forces between particles, thereby maintaining the system's stability and high anti-inflammatory and antioxidant effects under wide temperature range (5~45℃), freeze-thaw cycles, and strong light (4500 lux) conditions.

[0047] S03. Add a pH adjuster to the second solution to obtain the third solution. The addition of the pH adjuster not only regulates the system to a physiologically compatible pH range, but more importantly, it fine-tunes the charge distribution and molecular conformation of the main component and the compound component through ionization, thereby further enhancing their host-guest recognition ability and assembly thermodynamic stability.

[0048] The pH adjuster is added by first dissolving it in water to obtain a pH adjusting solution, and then adding the pH adjusting solution to the second solution to avoid fluctuations in the system environment and ensure the structural stability of the supramolecular self-assembly.

[0049] S04. Add the active synergist to the third solution and mix thoroughly to obtain a self-assembled supramolecular composition.

[0050] In an optional embodiment, the mixing process of the third solution and the active synergist is carried out by heating, with the heating temperature being 55°C to 60°C; for example, the heating temperature can be 55°C, 56°C, 57°C, 58°C, 59°C, 60°C or any value within the range of any two of these values.

[0051] Under the premise that the self-assembled body has been fully constructed and stabilized, the introduction of active synergistic ingredients, such as the amphiphilic properties of white willow bark extract and succinic acid, allows them to preferentially accumulate in the microenvironment or interface region of the self-assembled body. This does not damage the core inclusion framework, and through the multi-target synergistic effect of salicin slow-release regulation of keratin metabolism and succinic acid inhibition of lipid synthesis and NF-κB pathway, the oil-controlling, antibacterial and anti-inflammatory effects of the self-assembled supramolecular composition can be amplified.

[0052] The preparation method provided by this invention, through the preparation logic of nucleation, stabilization and loading, ensures that the self-assembled supramolecular composition has both high stability and high bioefficacy.

[0053] Thirdly, the present invention provides a formulation comprising a self-assembled supramolecular composition of any of the foregoing embodiments or a self-assembled supramolecular composition prepared by the preparation method of the foregoing embodiments.

[0054] In an optional implementation, the formulation includes a medical device or a cosmetic.

[0055] Preferably, the medical device includes medical dressings.

[0056] Preferably, the cosmetic is a functional cosmetic.

[0057] Preferably, the cosmetic formulation is any one of oil-based formulation, serum, lotion, emulsion, cream, mask or spray.

[0058] Preferably, the formulation is used for at least one of oil control, antibacterial, prevention and / or improvement of acne vulgaris, skin repair, skin anti-inflammatory and skin antioxidant.

[0059] Preferably, the antibacterial effect includes inhibition of Propionibacterium acnes.

[0060] Preferably, acne vulgaris includes at least one of pimples, blackheads, red pimples, and pustular pimples.

[0061] Preferably, the anti-inflammatory properties of the skin include at least one of skin soothing, skin redness reduction, anti-skin irritation, skin barrier repair, and improvement of skin sensitivity and redness.

[0062] Fourthly, the present invention provides the use of a self-assembled supramolecular composition of any of the foregoing embodiments or a self-assembled supramolecular composition prepared by the preparation method of the foregoing embodiments in the preparation of an agent for at least one of oil control, antibacterial, prevention and / or improvement of acne vulgaris, skin repair, skin anti-inflammation and skin anti-oxidation.

[0063] Preferably, the antibacterial effect includes inhibition of Propionibacterium acnes.

[0064] Preferably, acne vulgaris includes at least one of pimples, blackheads, red pimples, and pustular pimples.

[0065] Preferably, the anti-inflammatory properties of the skin include at least one of skin soothing, skin redness reduction, anti-skin irritation, skin barrier repair, and improvement of skin sensitivity and redness.

[0066] In an optional implementation, the formulation includes a medical device or a cosmetic.

[0067] In an optional implementation, the medical device includes a medical dressing.

[0068] The cosmetics are functional cosmetics.

[0069] Cosmetic preparations are at least one of the following: oil-based preparations, serums, lotions, emulsions, creams, masks, or sprays.

[0070] The features and performance of the present invention will be further described in detail below with reference to embodiments.

[0071] Terminology definition: In this invention, "room temperature" refers to the ambient temperature, which can be 20℃~30℃; in some embodiments, it is 22℃~28℃; in some embodiments, it is 24℃~26℃; and in some embodiments, it is 25℃.

[0072] The CAS numbers for resveratrol, quercetin, thymol, pachymectin, magnolol, thymol, cynomol, magnolol, thymol, cynomol, magnolol, magnolol, thy ...

[0073] "% (w / v)" represents the weight-volume percentage, that is, the number of grams of solute contained in every 100 mL of solution.

[0074] “wt%” indicates weight percentage.

[0075] "%vol" represents the volume percentage.

[0076] “v / v / v” represents the volume ratio.

[0077] "Final concentration" refers to the final concentration of a drug, stimulant, or test substance in the action medium after it has been added to the experimental system. It is the actual concentration that directly acts on cells, tissues, or organisms to produce biological effects.

[0078] The term "parts by weight" indicates the relative weight ratio between components; it is not a specific mass value, but a proportional relationship. For example, a self-assembled supramolecular composition contains 2 parts by weight of component A and 3 parts by weight of component B, which means that the weight ratio of component A to component B is 2:3.

[0079] The content of total phenols in magnolol is the total mass content of magnolol and honokiol.

[0080] Raw material source: 1. Magnolia officinalis bark extract: Product name: Magnolia officinalis extract; Product code: HPT98; Manufacturer: Hunan Heguang Biotechnology Co., Ltd.; INCI: Magnolia officinalis bark extract; Total phenols (and magnolol + honokiol) ≥ 98.0 wt% (The actual test result of the total phenols (and magnolol + honokiol) content in the Magnolia officinalis bark extract used in the following examples and comparative examples is 99.07 wt%); Preparation method: Using Magnolia officinalis ( Magnolia officinalis The product is obtained by extracting, separating, and refining the root bark of Rehd. under mild conditions using supercritical carbon dioxide (CO2).

[0081] Determination of honokiol and total honokiol content: High performance liquid chromatography (HPLC) was used for detection. The HPLC parameters were as follows: Column: ZORBAX StableBond C18, 250 mm × 4.6 mm, 5 μm; Column temperature: 30℃; Mobile phase: methanol: water: glacial acetic acid = 78: 22: 0.5 (v / v / v); Flow rate: 1.0 mL / min; Detection wavelength: 294 nm; Injection volume: 10 μL.

[0082] 2. White willow bark extract: Product name: White willow (SALIX ALBA) bark extract; Salicin content ≥98wt% (the actual test result of the salicin content in the white willow bark extract used in the following examples and comparative examples is 98.15wt%); Manufacturer: Xi'an Xiaocao Botanical Technology Co., Ltd.; Raw material reporting code: 001159-02921-6092.

[0083] 3. Glycyrrhiza uralensis extract: Product name: Glycyrrhiza chalcone A 21%; Manufacturer: Chenfeng Natural Herbs (Beijing) Technology Co., Ltd.; Product code: SHGC1001; The content of glycyrrhiza uralensis extract is ≥21wt% (the actual test result of the content of glycyrrhiza chalcone A in the Glycyrrhiza uralensis extract used in the following examples and comparative examples is 21.2wt%).

[0084] 4. Clostridium agar fortification: purchased from Qingdao Haibo, item number HB0286.

[0085] 5. Penicillin-Streptomycin: Contains 5000 U / mL penicillin and 5000 µg / mL streptomycin, purchased from Gibco, catalog number: 15070063.

[0086] 6. DMEM culture medium: purchased from Gibco, catalog number: 11965092.

[0087] 7. Complete culture medium: Fetal bovine serum, penicillin-streptomycin and DMEM medium are mixed to obtain complete culture medium. The concentration of fetal bovine serum in the complete culture medium is 10% vol, the concentration of penicillin is 100 U / mL and the concentration of streptomycin is 100 μg / mL.

[0088] 8. PBS buffer: Mix 2.83 g Na2HPO4·12H2O, 0.27 g KH2PO4 and 8.50 g NaCl with 800 mL of deionized water, stir until completely dissolved, bring the volume to 1000 mL, dispense and autoclave at 121 °C for 15 min to obtain PBS buffer.

[0089] 9. 0.1wt% sodium dodecyl sulfate solution: Dilute sodium dodecyl sulfate with PBS buffer to a concentration of 0.1wt%.

[0090] 10. 4% paraformaldehyde: Dilute paraformaldehyde with PBS buffer to a paraformaldehyde concentration of 4% (w / v).

[0091] 11. DPBS (Duborough Phosphate Buffer, Calcium- and Magnesium-Free): Manufacturer: CellWorld; Catalog Number: C0362-315.

[0092] 12. PPG-13-decyltetradecyl alcohol polyether-24: Manufacturer: Cosfa International Trading (Guangzhou) Co., Ltd.; Item No.: 111G419U2002EB17.

[0093] 13. Oleol polyether-20: Manufacturer: BASF (China) Co., Ltd.; Item No.: PRD 30530565; Molecular weight: 709.

[0094] 14. Lecithin: Manufacturer: Lipoid Kosmetik AG; Product No.: 228154; 368202; 368247; Molecular Weight: 758.06.

[0095] 15. Sophorolipid: Manufacturer: Shanghai Boku Biotechnology Co., Ltd.; Product No.: S25L02001BS; Molecular Weight: 688.8.

[0096] Example 1 This embodiment provides an oil-controlling and antibacterial self-assembled supramolecular composition, comprising, by weight 100 parts: 5 parts glycyrrhizic acid, 2 parts Magnolia officinalis bark extract, 0.1 parts Glycyrrhiza uralensis extract, 5 parts Salix babylonica bark extract, 1 part lecithin, 2 parts sophorolipid, 5 parts PPG-13-decyltetradecyl alcohol polyether-24, 40 parts dipropylene glycol, 2 parts ethoxydiethylene glycol, 2 parts L-arginine, and the balance being water.

[0097] This invention also provides a method for preparing the above-mentioned oil-controlling and antibacterial self-assembled supramolecular composition, comprising the following steps: S01. The main component (5 parts by weight of glycyrrhizic acid) and the compound components (2 parts by weight of Magnolia officinalis bark extract and 0.1 parts by weight of Glycyrrhiza uralensis extract) are added to a polyol (40 parts by weight of dipropylene glycol and 2 parts by weight of ethoxydiethylene glycol) and mixed. The mixture is then heated to 65°C to ensure that all raw materials are completely dissolved to obtain the first solution.

[0098] S02. Add surfactant (1 part by weight of lecithin, 2 parts by weight of sophorolipid and 5 parts by weight of PPG-13-decyltetradecyl alcohol polyether-24) to the first solution obtained in step S01 and mix well to obtain the second solution.

[0099] S03. Disperse the pH adjuster (2 parts by weight of L-arginine) in water until completely dissolved to obtain a pH adjusting solution; add the pH adjusting solution to the second solution obtained in step S02 and disperse it thoroughly to obtain a third solution.

[0100] S04. Add the active synergist (5 parts by weight of white willow bark extract) to the third solution obtained in step S03 and mix. Then heat to 60°C to ensure that all raw materials are completely dissolved to obtain a self-assembled supramolecular composition.

[0101] Example 2 This embodiment provides an oil-controlling and antibacterial self-assembled supramolecular composition, comprising, by weight 100 parts: 5 parts glycyrrhizic acid, 2 parts Magnolia officinalis bark extract, 1 part Glycyrrhiza uralensis extract, 5 parts Salix babylonica bark extract, 1 part lecithin, 2 parts sophorolipid, 6 parts PPG-13-decyltetradecyl alcohol polyether-24, 40 parts dipropylene glycol, 2 parts ethoxydiethylene glycol, 2 parts L-arginine, and the balance being water.

[0102] The preparation method is the same as in Example 1.

[0103] Example 3 This embodiment provides an oil-controlling and antibacterial self-assembled supramolecular composition, which, based on a total weight of 100 parts, comprises: 2.5 parts by weight of baicalin, 1 part by weight of Magnolia officinalis bark extract, 1 part by weight of cypressin, 2.5 parts by weight of Salix babylonica bark extract, 2 parts by weight of succinic acid, 1 part by weight of lecithin, 5 parts by weight of oleyl alcohol polyether-20, 30 parts by weight of dipropylene glycol, 5 parts by weight of glycerin, 1 part by weight of sodium hydroxide, and the balance being water.

[0104] The preparation method is the same as in Example 1.

[0105] Example 4 This embodiment provides an oil-controlling and antibacterial self-assembled supramolecular composition, which, based on a total weight of 100 parts, comprises: 1 part by weight of baicalin, 1 part by weight of Magnolia officinalis bark extract, 1 part by weight of cypressin, 2.5 parts by weight of Salix babylonica bark extract, 2 parts by weight of succinic acid, 1 part by weight of lecithin, 5 parts by weight of oleyl alcohol polyether-20, 30 parts by weight of dipropylene glycol, 5 parts by weight of glycerin, 1 part by weight of sodium hydroxide, and the balance being water.

[0106] The preparation method is the same as in Example 1.

[0107] Comparative Example 1 This comparative example provides a composition and its preparation method, which differs from Example 1 only in that hydroxypropyl-β-cyclodextrin is used instead of glycyrrhizic acid.

[0108] Comparative Example 2 This comparative example provides a composition and its preparation method, which differs from Example 3 only in that ginsenoside Rb1 is used instead of baicalin.

[0109] Comparative Example 3 This comparative example provides a composition and its preparation method, which differs from Example 1 only in that resveratrol is used instead of Magnolia officinalis bark extract.

[0110] Comparative Example 4 This comparative example provides a composition and its preparation method, which differs from Example 1 only in that quercetin is used instead of licorice extract.

[0111] Comparative Example 5 This comparative example provides a composition and its preparation method, which differs from Example 3 only in that thymol is used instead of physalisol.

[0112] Comparative Example 6 This comparative example provides a composition and its preparation method, which differs from Example 1 only in that Tween 80 is used instead of PPG-13-decyltetradecyl alcohol polyether-24.

[0113] Comparative Example 7 This comparative example provides a composition and its preparation method, which differs from Example 3 only in that polyglycerol-10 oleate is used instead of oleyl alcohol polyether-20.

[0114] Comparative Example 8 This comparative example provides a composition and its preparation method, which differs from Example 1 only in that: glycyrrhizic acid is 1 part by weight and PPG-13-decyltetradecyl alcohol polyether-24 is 1 part by weight.

[0115] Comparative Example 9 This comparative example provides a composition and its preparation method, which differs from Example 1 only in that: Magnolia officinalis bark extract and Glycyrrhiza uralensis extract were not added.

[0116] Comparative Example 10 This comparative example provides a composition and its preparation method, which differs from Example 1 only in that glycyrrhizic acid is not added.

[0117] Comparative Example 11 This comparative example provides a composition and its preparation method, which differs from Example 1 only in that: no white willow bark extract was added.

[0118] Comparative Example 12 This comparative example provides a composition with the same raw material composition as Example 1, the only difference being the preparation method. The preparation method of the composition provided in this comparative example is as follows: all raw materials are directly mixed and stirred evenly, and then heated to 60°C to dissolve completely.

[0119] Comparative Example 13 This comparative example provides a composition with the same raw material composition as Example 1 and a similar preparation method as Example 1. The only difference is that the active synergist is added together with the main component and the compound component into a polyol and stirred at 60°C until completely dissolved.

[0120] Experimental Example 1 1. High-temperature stability test: The compositions provided in the above examples and comparative examples were placed at 45°C to test the product stability (appearance and total phenol content of magnolia bark) for 3 months. The results are shown in Table 1 and Table 2.

[0121] 2. Low-temperature stability test: The compositions provided in the above examples and comparative examples were placed at 5°C to test the product stability (appearance) for 3 months. The results are shown in Table 1.

[0122] 3. Freeze-thaw cycle test: The compositions provided in the above examples and comparative examples were placed in a high and low temperature cycling chamber. The conditions were set as follows: placed at 45℃ for 24 hours, then restored to room temperature for 12 hours, then placed at -15℃ for 24 hours, and then restored to room temperature for 12 hours. This constitutes one freeze-thaw cycle. After six cycles of testing, the stability (appearance) of each composition was observed. The results are shown in Table 1.

[0123] 4. Light stability: The compositions provided in the above examples and comparative examples were irradiated under strong light (4500 lux) for 10 days to test the product stability (appearance and total phenol content of magnolia bark). The results are shown in Table 1 and Table 2.

[0124] Table 1. Appearance and stability of the composition

[0125] Note: "No abnormalities" indicates a yellow, transparent solution with no precipitate or crystals. "Becomes hazy" indicates slight precipitation.

[0126] Table 2. Retention rate of total phenols in the composition (unit: %)

[0127] Note: The retention rate of total magnolol content represents the percentage of total magnolol and honokiol content after stability storage compared to the total magnolol and honokiol content of the 0-day sample. The specific formula is as follows: The retention rate of total phenols in magnolia bark (%) = (total phenols in magnolia bark of the sample taken at the stability placement point ÷ total phenols in magnolia bark of the sample taken at day 0) × 100%.

[0128] As shown in Tables 1 and 2, the composition provided in the embodiments of the present invention can maintain stable appearance under high temperature (45°C), low temperature (5°C), freeze-thaw cycle test and light irradiation (4500 lux) conditions. Moreover, content detection revealed that the content retention rate of the key active ingredient, total phenols from magnolia bark, was high under both high temperature (45°C) and light irradiation (4500 lux) conditions, indicating that the composition provided in the present invention achieves stable loading of active ingredients through supramolecular self-assembly effect.

[0129] Comparative Examples 1 and 2 changed the choice of raw materials for the main components. In particular, Comparative Example 1 directly used cyclodextrin structure as the main component, which could not form a stable self-assembled supramolecular composition with at least one of the compound components among Magnolia officinalis bark extract, cypressin and Glycyrrhiza uralensis extract. Therefore, its stability was poor under high temperature (45℃), low temperature (5℃), freeze-thaw cycle test and light irradiation (4500 lux).

[0130] Comparative Examples 3-5 changed the selection of raw materials for the compound components. Although resveratrol, quercetin, and thymol also have similar biological activities to the compound components of this application, stability experiments have shown that the active substances provided by Comparative Examples 3-5 cannot form a stable self-assembled supramolecular composition in the system of this invention. Therefore, their stability is poor under high temperature (45°C), low temperature (5°C), freeze-thaw cycle test, and light irradiation (4500 lux).

[0131] Comparative Examples 6 and 7 changed the choice of surfactant raw materials. Although Tween 80 and polyglycerol-10 oleate are also commonly used surfactants, they cannot achieve the structural stabilization function of the self-assembled supramolecular composition in the system of the present invention. Therefore, the stability of the compositions provided by Comparative Examples 6 and 7 deteriorated rapidly under high temperature conditions (45°C), low temperature conditions (5°C), freeze-thaw cycle test and light irradiation conditions (4500 lux).

[0132] Comparative Examples 8-11 altered the ratios of different active substances or reduced the number of active substances, resulting in unstable structures of the compositions formed by the supramolecular self-assembly of the raw materials. Consequently, their stability deteriorated under high temperature (45°C), low temperature (5°C), freeze-thaw cycle tests, and light irradiation (4500 lux).

[0133] Comparative Examples 12 and 13 altered the mixing order of the raw materials in the composition. The essence of the addition order is to change the local concentration and contact order of the components in the reaction system, causing differences in the timing of interactions between different molecules. The preparation method provided in this embodiment of the invention first mixes the main component and the compound component to generate primary assembly units, and then adds secondary assembly units (surfactants, pH adjusters, and activity synergists) to construct higher-order structures, thereby forming stable self-assembled bodies. However, changing the mixing order in Comparative Examples 12 and 13 causes the first added components to preferentially interact and form metastable intermediates. Subsequent added components need to break the original interactions to participate in assembly. If the dissociation barrier of the metastable intermediate is high, the system will be "locked" in a kinetically metastable structure rather than the thermodynamically most stable structure. Therefore, the compositions of Comparative Examples 12 and 13 both exhibit stability problems such as precipitation.

[0134] Experiment Example 2: Oil Control Efficacy Test (using lipid droplet content test) (1) Group culture: SZ95 cells (human sebaceous gland cells) in the logarithmic growth phase were selected, and the cells were collected after trypsin digestion and prepared into a cell suspension. Cells were counted using a cell counter. A 1×10⁶ cell suspension was prepared using complete culture medium. 5Cell suspension of cells / mL was seeded into 96-well plates, with 100 μL added to each well. 100 μL of DPBS (Dubor's phosphate buffer, calcium- and magnesium-free) was added to the outer periphery of each well, and the plates were incubated at 37°C in a 5% CO2 incubator for 24 ± 2 h.

[0135] (2) Group design: Blank control group (BC group): No linoleic acid was added (no induction), no samples or intervention reagents were added, and only complete culture medium was added for culture.

[0136] Negative control group (NC group): Linoleic acid (final concentration 100 μg / mL) was added for induction, no sample / positive drug was added, and the group was co-cultured in complete culture medium (simple modeling group).

[0137] Positive control group (PC group): Linoleic acid (final concentration 100 μg / mL) was added for induction, and isotretinoin (final concentration 3 μg / mL, dissolved in DMSO) was added simultaneously, and the mixture was co-cultured in complete culture medium.

[0138] Sample group: Linoleic acid (final concentration 100 μg / mL) was added for induction, and samples from Example 1 (final concentrations of 0.01% (w / v), 0.005% (w / v) and 0.001% (w / v) respectively), Comparative Example 1 (final concentration 0.01% (w / v)), Comparative Example 3 (final concentration 0.01% (w / v)), Comparative Example 7 (final concentration 0.01% (w / v)), Comparative Example 11 (final concentration 0.01% (w / v)), and Comparative Example 13 (final concentration 0.01% (w / v)) were added simultaneously and co-cultured in complete culture medium.

[0139] Each group was set up with 3 replicates, and the experiment was repeated 3 times. The mean ± standard deviation (x ± s) was taken; then statistical analysis was performed.

[0140] (3) Sample addition process: After the culture in step (1), discard the original culture medium in the 96-well plate, gently rinse the cells once with DPBS (Dubor's phosphate buffer, calcium- and magnesium-free type), and discard the rinse solution; according to the group design in (2), carry out the sample addition operation. All samples, positive drugs and inducers are diluted with complete culture medium to ensure that the final volume of the system after administration is 100 μL / well. During the sample addition process, gently pipette and mix to avoid damaging the cells.

[0141] After the samples were added to each group, the cell culture plates were placed in a 37℃, 5% CO2 incubator and cultured for 24±2h.

[0142] (4) Detection: After step (3), discard the original culture medium in the cell plate, wash the cells once with DPBS (Dubor's phosphate buffer, calcium- and magnesium-free); add 100 μL of 4% paraformaldehyde to fix for 10 min, discard the fixative and wash twice with DPBS (Dubor's phosphate buffer, calcium- and magnesium-free); set up blank fluorescence correction wells (background blank wells) with no cells and only Nile red staining solution: no cells are seeded in the background blank wells, and the rest of the treatment is completely the same as the experimental wells: add 100 μL of 4% paraformaldehyde to fix for 10 min, discard the fixative and wash twice with DPBS (Dubor's phosphate buffer, calcium- and magnesium-free) to ensure that the treatment conditions and incubation time are completely synchronized with the experimental wells, so as to eliminate non-specific fluorescence interference caused by the well plate itself, DPBS (Dubor's phosphate buffer, calcium- and magnesium-free), Nile red staining solution and fixative solution.

[0143] Next, 100 μL of 10 μg / mL Nile Red staining solution was added to all experimental wells (blank control group, negative control group, positive control group, sample group) and cell-free fluorescence blank correction wells, and incubated at 37℃ in the dark for 10 min. The Nile Red staining solution was discarded, and the cells were washed three times with DPBS (Dubor's phosphate buffer, calcium- and magnesium-free). The cell plates were then transferred to the biological preparation room for fluorescence value measurement using a fluorescence microplate reader, and the relative lipid droplet content and lipid droplet content inhibition rate were calculated.

[0144] The formula for calculating the relative content of lipid droplets is: Relative content of lipid droplets (%) = T / C × 100%. Where, T: Nile red fluorescence value of the test sample; B: Nile red fluorescence value of the background blank well; BC: Nile red fluorescence value of the blank control group; NC: Nile red fluorescence value of the negative group.

[0145] The formula for calculating the lipid droplet content inhibition rate is: Lipid droplet content inhibition rate (%) = (1 - T / C) 100%. Wherein, T: Nile red fluorescence value of the test sample; B: Nile red fluorescence value of the background blank well; BC: Nile red fluorescence value of the blank control group; NC: Nile red fluorescence value of the negative group.

[0146] The calculated relative lipid droplet content and lipid droplet content inhibition rate are shown in Table 3.

[0147] Table 3. Results of lipid droplet content test

[0148] Note: "*" indicates a statistically significant difference compared with the negative control group, and the significance is statistically significant (P<0.05); "**" indicates a statistically significant difference compared with the negative control group, and the significance is highly significant (P<0.01); "***" indicates a statistically significant difference compared with the negative control group, and the significance is highly significant (P<0.001).

[0149] As shown in Table 3, when the self-assembled supramolecular composition provided in Example 1 of the present invention was tested at concentrations of 0.01% (w / v), 0.005% (w / v), and 0.001% (w / v), the relative lipid droplet content in the cells after the sample was applied was 72.93%, 64.29%, and 88.71%, respectively. Compared with the negative control group (100%), the inhibition rates were 27.07%, 35.71%, and 11.29%, respectively, all of which showed significant differences (P < 0.05), indicating a significant oil control effect. This demonstrates that the self-assembled supramolecular composition provided in the examples of the present invention has an excellent oil control effect.

[0150] Test Example 3: Antibacterial Efficacy Test (I) Materials and Reagents 1. Test strain: Propionibacterium acnes (ATCC 6919 (commercially available) or clinically isolated and validated strain; ATCC 6919 (commercially available) was used in this test).

[0151] 2. Culture medium: Weigh 38g of reinforced Clostridium agar powder, dissolve it in 1000ml of water, heat to boiling to dissolve, then autoclave at 121℃ for 15min, and place in a 45℃~50℃ water bath for later use.

[0152] 3. Preparation of double concentration culture medium (this culture medium will be used to dilute the antibacterial (inhibitory) solution or suspension): Weigh 76g of reinforced Clostridium agar dry powder, dissolve it in 1000ml of water, heat to boiling to dissolve, then autoclave at 121℃ for 15min, and place in a 45℃~50℃ water bath for later use.

[0153] (II) Experimental Procedure 1. Preparation of antibacterial mixture: Under aseptic conditions, take 5 mL of the sample from Example 1 and place it in 45 mL of PBS buffer. Shake well to dissolve and obtain the antibacterial mixture.

[0154] 2. Preparation of antibacterial solutions of various concentrations: The antibacterial mixture obtained in step 1 was serially diluted with PBS buffer to obtain test solutions of different concentrations (twice the effective concentration in Table 4), and the antibacterial solutions of various concentrations were placed in a water bath at 45℃~50℃ for later use.

[0155] 3. Preparation of culture media containing a series of antibacterial solutions: Take 10 mL of each of the series of antibacterial solutions and add it to a Petri dish. Add 10 mL of double-concentration culture medium (prepared in a 45℃~50℃ water bath) to the Petri dish while shaking the dish to ensure thorough mixing of the antibacterial solutions and culture medium. Allow the mixture to solidify before use.

[0156] 4. Blank control group: Add 10 mL of PBS buffer to a Petri dish. Add 10 mL of double-concentration culture medium (prepared in a 45℃~50℃ water bath) to the Petri dish, shaking the dish while adding the medium to ensure thorough mixing of the PBS buffer and culture medium. Allow the mixture to solidify before use.

[0157] 5. Using a pipette, pipette 2 μL of each sample (containing approximately 1 × 10⁻⁶ bacteria). 7 CFU / mL bacterial suspension was inoculated onto Petri dishes containing a series of concentrations of antibacterial solution obtained in step 3 and the blank control group obtained in step 4. The diameter of the bacterial suspension ring formed after inoculation was approximately 5 mm to 8 mm (the bacterial count per spot was approximately 2 × 10⁻⁶). 4 CFU).

[0158] 6. After inoculation, the corresponding bacterial strain was placed on the petri dish and anaerobic cultured at 37℃ for 48 hours. The colony growth was then observed. The results are shown in Table 4.

[0159] Table 4. Effects of the composition provided in Example 1 on Propionibacterium acnes

[0160] Note: In the table, "+" indicates visible growth of the strain; "-" indicates no visible growth of the strain, with the blank control group as the growth reference.

[0161] As shown in Table 4, the minimum inhibitory concentration (MIC) of the self-assembled supramolecular composition provided in the embodiments of the present invention is 0.2% (v / v). The composition has excellent antibacterial effect against Propionibacterium acnes at concentrations exceeding 0.2% (v / v) and can be used in acne treatment products to prevent and / or improve acne vulgaris (pimples, blackheads, red pimples and pustular pimples).

[0162] Experiment 4: Anti-inflammatory efficacy experiment (1) Group design: Blank control group (BC group): No sodium dodecyl sulfate solution was added (no induction), no samples or intervention reagents were added, and only complete culture medium was added for culture.

[0163] Negative control group (NC group): 25 μL of 0.1wt% sodium dodecyl sulfate solution was added for induction, without adding samples / positive drugs, and co-cultured in complete culture medium (simple modeling group).

[0164] Positive control group (PC group): 25 μL of 0.1wt% sodium dodecyl sulfate solution was added for induction, and dexamethasone at a concentration of 0.01% (w / v) was added simultaneously. The mixture was co-cultured in complete culture medium.

[0165] Sample group: 25 μL of 0.1wt% sodium dodecyl sulfate solution was added for induction, and the samples from Example 1 (concentrations of 0.1% (w / v), 1% (w / v) and 2% (w / v) were added simultaneously and co-cultured in complete culture medium.

[0166] (2) Experimental method: The 3D epidermal skin model (EpiKutis®) was transferred to a 6-well plate (0.9mL EpiGrowth culture medium was added in advance, Guangdong Boxi Shaanxi Branch), and the test group number was marked on the 6-well plate.

[0167] According to the group design in (1) above, 25 μL of 0.1wt% sodium dodecyl sulfate solution was added to the surface of the 3D epidermal skin model in the corresponding wells of the 6-well plate of the negative control group (NC group), positive control group (PC group) and all sample groups for induction, while 25 μL of water was added to the blank control group (BC group); then each group was incubated at 37℃ and 5%CO2 for 30 min.

[0168] After incubation, proceed with the following procedures: Blank control group (BC group): 12.5 μL of water was evenly applied to the surface of the skin model; Negative control group (NC group): 12.5 μL of water was evenly applied to the surface of the skin model; Positive control group (PC group): 12.5 μL of dexamethasone working solution (0.01% (w / v)) at the concentration specified in the (1) grouping design (solvent is water) was evenly applied to the surface of the skin model; For each sample group: Apply 12.5 μL of the working solution of Example 1 sample (0.1% (w / v), 1% (w / v), 2% (w / v), with water as the solvent) of the corresponding concentration in the group design in (1) evenly to the surface of the skin model to ensure consistent dosage and uniform distribution.

[0169] The treated 6-well plates were placed in a CO2 incubator and incubated at 37°C with 5% CO2 for 24 hours. After incubation, the plates were removed, and the model surface was gently rinsed three times with PBS buffer to thoroughly remove any residual test material and culture medium. Then, the residual liquid on the model surface was gently wiped away with a sterile cotton swab. The model used for testing was fixed with 4% paraformaldehyde for 24 hours, followed by immunofluorescence detection to calculate the NF-κB inhibition rate. The formula for calculating the NF-κB inhibition rate is as follows:

[0170] The detection and calculation results of the NF-κB inhibition experiment are shown in Table 5.

[0171] Table 5. Results of NF-κB immunofluorescence analysis

[0172] Note: The relative IOD average represents the average integrated optical density after normalization based on the blank control group, and is used to quantitatively evaluate the content of NF-κB.

[0173] As shown in Table 5, based on the 3D epidermal skin model (EpiKutis®), compared with the NC group, the NF-κB content in the 0.1% (w / v) administration concentration, 1% (w / v) administration concentration, and 2% (w / v) administration concentration groups were significantly reduced, with inhibition rates of 24.89%, 36.30%, and 52.74%, respectively. This indicates that the supramolecular composition provided by the present invention has excellent anti-inflammatory effects, can inhibit the inflammatory factor NF-κB, and can be used for skin soothing, skin redness reduction, anti-skin irritation, repair of the skin barrier, and improvement of sensitive and red skin.

[0174] Experimental Example 5: Particle Size Detection The self-assembled supramolecular compositions provided in Example 1, Comparative Example 1, and Comparative Example 12 were dispersed in the same solution, and the hydrodynamic diameter and particle size distribution of the self-assembled supramolecular compositions in the solution were measured using dynamic light scattering (DLS).

[0175] The particle size distribution of a stable self-assembled supramolecular composition must meet the following requirements: unimodal distribution, PDI < 0.3 indicating good assembly uniformity; and the particle size must match the structure of the self-assembled supramolecular composition: 10–200 nm. The detection results are shown in Table 6. Figures 1-3 As shown.

[0176] Figures 1-3 In the diagram, steady state indicates the particle scattering signal that is real and stable in the sample itself; unfiltered indicates that the result fully retains all signal information; if the unfiltered result differs significantly from the steady state result, it indicates that there are a small number of random large particles or interference factors in the sample.

[0177] Table 6 Particle size detection results

[0178] From Table 6 and Figures 1-3It can be seen that the self-assembled supramolecular composition provided in Example 1 of the present invention has a particle size of 12.35 nm and a PDI of 0.1313 < 0.3, indicating that the composition forms a stable and uniform self-assembled structure. However, the PDI of Comparative Example 1 and Comparative Example 12 are both > 0.3, indicating that agglomeration occurs and each component is only dispersed in the solution without forming a stable supramolecular self-assembled structure.

[0179] The present invention provides an oil-controlling and antibacterial self-assembled supramolecular composition, its preparation method, application, and formulation, which has at least the following advantages: The self-assembled supramolecular composition provided in this invention has excellent oil-controlling, antibacterial and anti-inflammatory effects, and can be used to prepare formulations for at least one of oil control, antibacterial, prevention and / or improvement of acne vulgaris, skin repair, skin anti-inflammation and skin anti-oxidation.

[0180] This invention utilizes a key raw material combination of main components, compound components, active synergistic components, and surfactants to obtain a self-assembled supramolecular composition that can maintain stable appearance under high temperature (45°C), low temperature (5°C), freeze-thaw cycle test, and light irradiation (4500 lux) conditions. This is beneficial for improving the stability of the content of active ingredients in the self-assembled supramolecular composition under various storage conditions.

[0181] This invention primarily uses a combination of natural ingredients, greatly reducing the use of chemical activators, improving product safety and tolerability, and solving the problem of potential side effects from traditional acne treatment products.

[0182] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. A self-assembled supramolecular composition, characterized in that, By weight, it includes: 7.5-13 parts by weight of supramolecular self-assembly polymer host, 6-9 parts by weight of surfactant, 35-42 parts by weight of polyol, 1-2 parts by weight of pH adjuster and 34-50.5 parts by weight of water; The raw materials of the supramolecular self-assembly polymeric host include a main component, compound components, and active synergistic components in a mass ratio of (1~5):(2~3):(4.5~5); The main components include at least one of glycyrrhizic acid and baicalin; The compound ingredients include at least one of the following: Magnolia officinalis bark extract, cypressin, and Glycyrrhiza uralensis extract; The active synergistic ingredients include at least one of white willow bark extract and succinic acid.

2. The self-assembled supramolecular composition according to claim 1, characterized in that, The extract of *Glycyrrhiza uralensis* contains glycyrrhizin A; the content of glycyrrhizin A in the extract is 21.0 wt% to 22.0 wt%. And / or, the Magnolia officinalis bark extract includes total magnolol, the content of total magnolol in the Magnolia officinalis bark extract is ≥98.0 wt%; the total magnolol includes magnolol and at least one of magnolol; And / or, the white willow bark extract includes salicin, and the content of salicin in the white willow bark extract is ≥98wt%.

3. The self-assembled supramolecular composition according to claim 1, characterized in that, The surfactant includes at least one of oleyl alcohol polyether-20, lecithin, sophorolipid and PPG-13-decyltetradecyl alcohol polyether-24; And / or, the polyol comprises at least one of dipropylene glycol, ethoxydiethylene glycol, and glycerol; And / or, the pH adjuster includes at least one of L-arginine and sodium hydroxide.

4. A method for preparing the self-assembled supramolecular composition according to any one of claims 1 to 3, characterized in that, include: The main component, the compound component, and the polyol are mixed evenly to obtain a first solution; Add the surfactant to the first solution and mix thoroughly to obtain a second solution; Add the pH adjuster to the second solution to obtain a third solution; The active synergist is added to the third solution and mixed evenly to obtain the self-assembled supramolecular composition.

5. The preparation method according to claim 4, characterized in that, The first solution is obtained by mixing with heat at a temperature of 45°C to 65°C. And / or, before adding the pH adjuster to the second solution, the method further includes dissolving the pH adjuster in water to obtain a pH adjusting solution, and then adding the pH adjusting solution to the second solution; And / or, the mixing process of the third solution and the active synergistic ingredient is carried out by heating, with the heating temperature being 55℃~60℃.

6. A formulation, characterized in that, This includes the self-assembled supramolecular composition according to any one of claims 1 to 3, or the self-assembled supramolecular composition prepared by the preparation method according to claim 4 or 5.

7. The formulation according to claim 6, characterized in that, The formulation includes medical devices or cosmetics.

8. The use of a self-assembled supramolecular composition according to any one of claims 1 to 3, or a self-assembled supramolecular composition prepared by the preparation method according to claim 4 or 5, in the preparation of an formulation for at least one of oil control, antibacterial, prevention and / or improvement of acne vulgaris, skin repair, skin anti-inflammatory and skin antioxidant.

9. The application according to claim 8, characterized in that, The formulation includes medical devices or cosmetics.

10. The application according to claim 9, characterized in that, The medical device includes medical dressings; The cosmetics in question are functional cosmetics; The cosmetic product is formulated in at least one of the following forms: oil-based preparation, serum, lotion, cream, mask, or spray.

Images